HomeAI · summaries
Storia in 5 fonti
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
- ·
statnews.com
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.
- ·
endpoints.news
Alnylam signs its first AI discovery deal with RNA specialist Inceptive
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.
- ·
biopharmadive.com
Alnylam, Inceptive ink AI deal potentially worth $2B
The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
- ·
AI titans push Congress for DNA safeguards
Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
- ·
benzinga.com
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Alnylam Pharmaceuticals (
Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish price targets.